APO Research
Talk to an analyst

APO RESEARCH · REPORT

Aldult CAR T-cell Therapy

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Aldult CAR T-cell Therapy Market Analysis and Forecast 2026-2032

3 May 2026240 pages

Choose your research edition.

Industry ResearchAldult CAR T-cell Therapy Industry Research Report 2026110 pages · $2,950 USDIndustry Growth & TrendsGlobal Aldult CAR T-cell Therapy Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Aldult CAR T-cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Aldult CAR T-cell Therapy Market Outlook and Growth Opportunities 2026185 pages · $4,250 USDMarket Analysis & ForecastGlobal Aldult CAR T-cell Therapy Market Analysis and Forecast 2026-2032240 pages · $4,950 USD

Market perspective

The global Aldult CAR T-cell Therapy market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Aldult CAR T-cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Aldult CAR T-cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Aldult CAR T-cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Aldult CAR T-cell Therapy is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Aldult CAR T-cell Therapy include Bristol Myers Squibb，BMS, Johnson & Johnson, Gilead Sciences, Novartis, JW Therapeutics, Imunopharm Technology Co., Ltd., CARsgen Therapeutics and Cartesian Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Aldult CAR T-cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Aldult CAR T-cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Aldult CAR T-cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Aldult CAR T-cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Aldult CAR T-cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Aldult CAR T-cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

Aldult CAR T-cell Therapy Segment by Company

Bristol Myers Squibb，BMS

Johnson & Johnson

Gilead Sciences

Novartis

JW Therapeutics

Imunopharm Technology Co., Ltd.

CARsgen Therapeutics

Cartesian Therapeutics

Aldult CAR T-cell Therapy Segment by Type

CD19

BCMA

Others

Aldult CAR T-cell Therapy Segment by Application

Multiple Myeloma

B-Cell Lymphoma (BCL)

Acute Lymphoblastic Leukemia (ALL)

Others

Aldult CAR T-cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aldult CAR T-cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Aldult CAR T-cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aldult CAR T-cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Aldult CAR T-cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Aldult CAR T-cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Aldult CAR T-cell Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Aldult CAR T-cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. CD19 Major Player Table 3. BCMA Major Player Table 4. Others Major Player Table 5. Global Aldult CAR T-cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Multiple Myeloma Major Player Table 7. B-Cell Lymphoma (BCL) Major Player Table 8. Acute Lymphoblastic Leukemia (ALL) Major Player Table 9. Others Major Player Table 10. Aldult CAR T-cell Therapy Industry Trends Table 11. Aldult CAR T-cell Therapy Industry Drivers Table 12. Aldult CAR T-cell Therapy Industry Opportunities and Challenges Table 13. Aldult CAR T-cell Therapy Industry Restraints Table 14. Global Aldult CAR T-cell Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 15. Global Aldult CAR T-cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 16. Global Aldult CAR T-cell Therapy Market Share by Region (2021-2026) Table 17. Global Aldult CAR T-cell Therapy Market Size by Region (2027-2032) & (US$ Million) Table 18. Global Aldult CAR T-cell Therapy Market Share by Region (2027-2032) Table 19. Global Aldult CAR T-cell Therapy Revenue by Players (US$ Million) & (2021-2026) Table 20. Global Aldult CAR T-cell Therapy Revenue Market Share by Players (2021-2026) Table 21. Global Aldult CAR T-cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 22. Global Aldult CAR T-cell Therapy Key Players Headquarters & Area Served Table 23. Global Aldult CAR T-cell Therapy Players, Product Type & Application Table 24. Global Aldult CAR T-cell Therapy Players Establishment Date Table 25. Global Players Market Concentration Ratio (CR5 and HHI) Table 26. Global Aldult CAR T-cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 27. Global Aldult CAR T-cell Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Aldult CAR T-cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 29. Global Aldult CAR T-cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 30. Global Aldult CAR T-cell Therapy Revenue Market Share by Type (2021-2026) Table 31. Global Aldult CAR T-cell Therapy Revenue Market Share by Type (2027-2032) Table 32. Global Aldult CAR T-cell Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Aldult CAR T-cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 34. Global Aldult CAR T-cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 35. Global Aldult CAR T-cell Therapy Revenue Market Share by Application (2021-2026) Table 36. Global Aldult CAR T-cell Therapy Revenue Market Share by Application (2027-2032) Table 37. Bristol Myers Squibb，BMS Company Information Table 38. Bristol Myers Squibb，BMS Business Overview Table 39. Bristol Myers Squibb，BMS Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. Bristol Myers Squibb，BMS Aldult CAR T-cell Therapy Product Portfolio Table 41. Bristol Myers Squibb，BMS Recent Development Table 42. Johnson & Johnson Company Information Table 43. Johnson & Johnson Business Overview Table 44. Johnson & Johnson Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Johnson & Johnson Aldult CAR T-cell Therapy Product Portfolio Table 46. Johnson & Johnson Recent Development Table 47. Gilead Sciences Company Information Table 48. Gilead Sciences Business Overview Table 49. Gilead Sciences Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Gilead Sciences Aldult CAR T-cell Therapy Product Portfolio Table 51. Gilead Sciences Recent Development Table 52. Novartis Company Information Table 53. Novartis Business Overview Table 54. Novartis Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Novartis Aldult CAR T-cell Therapy Product Portfolio Table 56. Novartis Recent Development Table 57. JW Therapeutics Company Information Table 58. JW Therapeutics Business Overview Table 59. JW Therapeutics Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. JW Therapeutics Aldult CAR T-cell Therapy Product Portfolio Table 61. JW Therapeutics Recent Development Table 62. Imunopharm Technology Co., Ltd. Company Information Table 63. Imunopharm Technology Co., Ltd. Business Overview Table 64. Imunopharm Technology Co., Ltd. Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Imunopharm Technology Co., Ltd. Aldult CAR T-cell Therapy Product Portfolio Table 66. Imunopharm Technology Co., Ltd. Recent Development Table 67. CARsgen Therapeutics Company Information Table 68. CARsgen Therapeutics Business Overview Table 69. CARsgen Therapeutics Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. CARsgen Therapeutics Aldult CAR T-cell Therapy Product Portfolio Table 71. CARsgen Therapeutics Recent Development Table 72. Cartesian Therapeutics Company Information Table 73. Cartesian Therapeutics Business Overview Table 74. Cartesian Therapeutics Aldult CAR T-cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Cartesian Therapeutics Aldult CAR T-cell Therapy Product Portfolio Table 76. Cartesian Therapeutics Recent Development Table 77. North America Aldult CAR T-cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 78. North America Aldult CAR T-cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 79. North America Aldult CAR T-cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 80. North America Aldult CAR T-cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 81. North America Aldult CAR T-cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 82. North America Aldult CAR T-cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 83. North America Aldult CAR T-cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 84. Europe Aldult CAR T-cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 85. Europe Aldult CAR T-cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 86. Europe Aldult CAR T-cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 87. Europe Aldult CAR T-cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 88. Europe Aldult CAR T-cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. Europe Aldult CAR T-cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 90. Europe Aldult CAR T-cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 91. China Aldult CAR T-cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 92. China Aldult CAR T-cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 93. China Aldult CAR T-cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 94. China Aldult CAR T-cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 95. Asia Aldult CAR T-cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 96. Asia Aldult CAR T-cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 97. Asia Aldult CAR T-cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 98. Asia Aldult CAR T-cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 99. Asia Aldult CAR T-cell Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Asia Aldult CAR T-cell Therapy Revenue by Region (US$ Million) & (2021-2026) Table 101. Asia Aldult CAR T-cell Therapy Revenue by Region (US$ Million) & (2027-2032) Table 102. SAMEA Aldult CAR T-cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 103. SAMEA Aldult CAR T-cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 104. SAMEA Aldult CAR T-cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 105. SAMEA Aldult CAR T-cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 106. SAMEA Aldult CAR T-cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. SAMEA Aldult CAR T-cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 108. SAMEA Aldult CAR T-cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 109. Research Programs/Design for This Report Table 110. Authors List of This Report Table 111. Secondary Sources Table 112. Primary Sources List of Figures Figure 1. Aldult CAR T-cell Therapy Image Figure 2. Global Aldult CAR T-cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Aldult CAR T-cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. CD19 Image Figure 5. BCMA Image Figure 6. Others Image Figure 7. Global Aldult CAR T-cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Aldult CAR T-cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 9. Multiple Myeloma Image Figure 10. B-Cell Lymphoma (BCL) Image Figure 11. Acute Lymphoblastic Leukemia (ALL) Image Figure 12. Others Image Figure 13. Global Aldult CAR T-cell Therapy Market Size (US$ Million) & (2021-2032) Figure 14. Global Aldult CAR T-cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Aldult CAR T-cell Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 16. Global Aldult CAR T-cell Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 18. Global Aldult CAR T-cell Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Aldult CAR T-cell Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Aldult CAR T-cell Therapy Revenue Market Share by Type (2021-2032) Figure 21. Global Aldult CAR T-cell Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Aldult CAR T-cell Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 23. Global Aldult CAR T-cell Therapy Revenue Market Share by Application (2021-2032) Figure 24. North America Aldult CAR T-cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 25. North America Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032) Figure 26. North America Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032) Figure 27. North America Aldult CAR T-cell Therapy Revenue Share by Country (2021-2032) Figure 28. United States Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Canada Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Mexico Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Europe Aldult CAR T-cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 32. Europe Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032) Figure 33. Europe Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032) Figure 34. Europe Aldult CAR T-cell Therapy Revenue Share by Country (2021-2032) Figure 35. Germany Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. France Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. U.K. Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Italy Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Spain Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Russia Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Netherlands Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Nordic Countries Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. China Aldult CAR T-cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. China Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032) Figure 45. China Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032) Figure 46. Asia Aldult CAR T-cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 47. Asia Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032) Figure 48. Asia Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032) Figure 49. Asia Aldult CAR T-cell Therapy Revenue Share by Region (2021-2032) Figure 50. Japan Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. South Korea Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. India Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Australia Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Taiwan Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Southeast Asia Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. SAMEA Aldult CAR T-cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 57. SAMEA Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032) Figure 58. SAMEA Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032) Figure 59. SAMEA Aldult CAR T-cell Therapy Revenue Share by Country (2021-2032) Figure 60. Brazil Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Argentina Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Chile Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Colombia Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Peru Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Saudi Arabia Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Israel Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. UAE Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Turkey Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Iran Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Egypt Aldult CAR T-cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • CD19
  • BCMA
  • Others
Applications
  • Multiple Myeloma
  • B-Cell Lymphoma (BCL)
  • Acute Lymphoblastic Leukemia (ALL)
  • Others
Companies covered
  • Bristol Myers Squibb，BMS
  • Johnson & Johnson
  • Gilead Sciences
  • Novartis
  • JW Therapeutics
  • Imunopharm Technology Co., Ltd.
  • CARsgen Therapeutics
  • Cartesian Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Aldult CAR T-cell Therapy Market by Type
  3. 1.2.1 Global Aldult CAR T-cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 CD19
  5. 1.2.3 BCMA
  6. 1.2.4 Others
  7. 1.3 Aldult CAR T-cell Therapy Market by Application
  8. 1.3.1 Global Aldult CAR T-cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Multiple Myeloma
  10. 1.3.3 B-Cell Lymphoma (BCL)
  11. 1.3.4 Acute Lymphoblastic Leukemia (ALL)
  12. 1.3.5 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Aldult CAR T-cell Therapy Market Dynamics
  1. 2.1 Aldult CAR T-cell Therapy Industry Trends
  2. 2.2 Aldult CAR T-cell Therapy Industry Drivers
  3. 2.3 Aldult CAR T-cell Therapy Industry Opportunities and Challenges
  4. 2.4 Aldult CAR T-cell Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Aldult CAR T-cell Therapy Market Perspective (2021-2032)
  2. 3.2 Global Aldult CAR T-cell Therapy Growth Trends by Region
  3. 3.2.1 Global Aldult CAR T-cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Aldult CAR T-cell Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Aldult CAR T-cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Aldult CAR T-cell Therapy Revenue by Players
  2. 4.1.1 Global Aldult CAR T-cell Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Aldult CAR T-cell Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Aldult CAR T-cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Aldult CAR T-cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Aldult CAR T-cell Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Aldult CAR T-cell Therapy Players, Product Type & Application
  8. 4.5 Global Aldult CAR T-cell Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Aldult CAR T-cell Therapy Market CR5 and HHI
  11. 4.6.3 2025 Aldult CAR T-cell Therapy Tier 1, Tier 2, and Tier 3
5 Aldult CAR T-cell Therapy Market Size by Type
  1. 5.1 Global Aldult CAR T-cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Aldult CAR T-cell Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Aldult CAR T-cell Therapy Revenue Market Share by Type (2021-2032)
6 Aldult CAR T-cell Therapy Market Size by Application
  1. 6.1 Global Aldult CAR T-cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Aldult CAR T-cell Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Aldult CAR T-cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol Myers Squibb，BMS
  2. 7.1.1 Bristol Myers Squibb，BMS Company Information
  3. 7.1.2 Bristol Myers Squibb，BMS Business Overview
  4. 7.1.3 Bristol Myers Squibb，BMS Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol Myers Squibb，BMS Aldult CAR T-cell Therapy Product Portfolio
  6. 7.1.5 Bristol Myers Squibb，BMS Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Aldult CAR T-cell Therapy Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Gilead Sciences
  14. 7.3.1 Gilead Sciences Company Information
  15. 7.3.2 Gilead Sciences Business Overview
  16. 7.3.3 Gilead Sciences Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Gilead Sciences Aldult CAR T-cell Therapy Product Portfolio
  18. 7.3.5 Gilead Sciences Recent Developments
  19. 7.4 Novartis
  20. 7.4.1 Novartis Company Information
  21. 7.4.2 Novartis Business Overview
  22. 7.4.3 Novartis Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Novartis Aldult CAR T-cell Therapy Product Portfolio
  24. 7.4.5 Novartis Recent Developments
  25. 7.5 JW Therapeutics
  26. 7.5.1 JW Therapeutics Company Information
  27. 7.5.2 JW Therapeutics Business Overview
  28. 7.5.3 JW Therapeutics Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 JW Therapeutics Aldult CAR T-cell Therapy Product Portfolio
  30. 7.5.5 JW Therapeutics Recent Developments
  31. 7.6 Imunopharm Technology Co., Ltd.
  32. 7.6.1 Imunopharm Technology Co., Ltd. Company Information
  33. 7.6.2 Imunopharm Technology Co., Ltd. Business Overview
  34. 7.6.3 Imunopharm Technology Co., Ltd. Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Imunopharm Technology Co., Ltd. Aldult CAR T-cell Therapy Product Portfolio
  36. 7.6.5 Imunopharm Technology Co., Ltd. Recent Developments
  37. 7.7 CARsgen Therapeutics
  38. 7.7.1 CARsgen Therapeutics Company Information
  39. 7.7.2 CARsgen Therapeutics Business Overview
  40. 7.7.3 CARsgen Therapeutics Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 CARsgen Therapeutics Aldult CAR T-cell Therapy Product Portfolio
  42. 7.7.5 CARsgen Therapeutics Recent Developments
  43. 7.8 Cartesian Therapeutics
  44. 7.8.1 Cartesian Therapeutics Company Information
  45. 7.8.2 Cartesian Therapeutics Business Overview
  46. 7.8.3 Cartesian Therapeutics Aldult CAR T-cell Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Cartesian Therapeutics Aldult CAR T-cell Therapy Product Portfolio
  48. 7.8.5 Cartesian Therapeutics Recent Developments
8 North America
  1. 8.1 North America Aldult CAR T-cell Therapy Revenue (2021-2032)
  2. 8.2 North America Aldult CAR T-cell Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Aldult CAR T-cell Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Aldult CAR T-cell Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Aldult CAR T-cell Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Aldult CAR T-cell Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Aldult CAR T-cell Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Aldult CAR T-cell Therapy Revenue by Country
  11. 8.6.1 North America Aldult CAR T-cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Aldult CAR T-cell Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Aldult CAR T-cell Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Aldult CAR T-cell Therapy Revenue (2021-2032)
  2. 9.2 Europe Aldult CAR T-cell Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Aldult CAR T-cell Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Aldult CAR T-cell Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Aldult CAR T-cell Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Aldult CAR T-cell Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Aldult CAR T-cell Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Aldult CAR T-cell Therapy Revenue by Country
  11. 9.6.1 Europe Aldult CAR T-cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Aldult CAR T-cell Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Aldult CAR T-cell Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Aldult CAR T-cell Therapy Revenue (2021-2032)
  2. 10.2 China Aldult CAR T-cell Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Aldult CAR T-cell Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Aldult CAR T-cell Therapy Revenue by Type (2027-2032)
  5. 10.3 China Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Aldult CAR T-cell Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Aldult CAR T-cell Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Aldult CAR T-cell Therapy Revenue by Application (2027-2032)
  9. 10.5 China Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Aldult CAR T-cell Therapy Revenue (2021-2032)
  2. 11.2 Asia Aldult CAR T-cell Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Aldult CAR T-cell Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Aldult CAR T-cell Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Aldult CAR T-cell Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Aldult CAR T-cell Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Aldult CAR T-cell Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Aldult CAR T-cell Therapy Revenue by Country
  11. 11.6.1 Asia Aldult CAR T-cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Aldult CAR T-cell Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Aldult CAR T-cell Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Aldult CAR T-cell Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Aldult CAR T-cell Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Aldult CAR T-cell Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Aldult CAR T-cell Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Aldult CAR T-cell Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Aldult CAR T-cell Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Aldult CAR T-cell Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Aldult CAR T-cell Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Aldult CAR T-cell Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Aldult CAR T-cell Therapy Revenue by Country
  11. 12.6.1 SAMEA Aldult CAR T-cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Aldult CAR T-cell Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Aldult CAR T-cell Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst